Company intelligence / Profile preview

EKPAC Group

Ownership: Private
Employees: ~73
Development stage: Commercial

Overview

Distributes Sensus SRT‑100™ systems for non-melanoma skin cancer and keloid treatment in China and Hong Kong. Over 40 units installed in hospitals and clinics across China as of early 2021. No proprietary clinical results as it acts as distributor.

Therapeutic areas: OncologyDermatology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Sensus Healthcare Inc. — exclusive distribution of SRT‑100™ systems in China/Hong Kong since January 2021

Beyond the preview

Go deeper on EKPAC Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EKPAC Group.

Explore the full profile